MaxCyte MXCT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$44.63M-8.7% | -$41.06M-8.3% | -$37.92M-60.9% | -$23.57M-23.5% | ||
| $4.34M+0.6% | $4.32M+3.5% | $4.17M+54.6% | $2.7M+89.5% | ||
| $9.21M-29.6% | $13.08M-6.4% | $13.98M+18.9% | $11.75M+47.7% | ||
| $3.55M— | —— | —— | —— | ||
| -$287K— | —— | —— | —— | ||
| -$1.15M+14.8% | -$1.35M+76.1% | -$5.65M— | —— | ||
| —— | -$1.36M-130% | $4.53M+29.8% | $3.49M+131% | ||
| —— | —— | $3.25M+2,268% | -$150K— | ||
| —— | $1.21M— | —— | —— | ||
| —— | -$9K— | —— | $871K+1,285% | ||
| —— | —— | —— | —— | ||
| $802K+68.8% | $475K+20.3% | $395K-48.5% | $767K— | ||
| -$1.16M-63.2% | -$709K-433% | -$133K— | —— | ||
| -$34.41M-24.6% | -$27.61M-21.8% | -$22.67M-44.4% | -$15.7M-47.0% | ||
| $1.77M+7.1% | $1.65M-55.4% | $3.7M-80.0% | $18.48M+382% | ||
| —— | —— | —— | —— | ||
| $126.29M-16.3% | $150.86M-40.9% | $255.1M— | —— | ||
| $155.76M-2.3% | $159.44M-49.2% | $313.77M+10.3% | $284.6M+267% | ||
| —— | —— | —— | —— | ||
| $25.94M— | —— | $59.12M— | —— | ||
| $432K-72.9% | $1.6M-14.8% | $1.87M-35.1% | $2.89M— | ||
| $656K-68.1% | $2.06M-4.1% | $2.14M-25.8% | $2.89M-98.8% | ||
| —— | —— | —— | -$36.72M— | ||
| $2.65M-57.6% | $6.24M-12.3% | $7.12M+167% | $2.67M+3,694% | ||
| —— | —— | —— | —— | ||
| -$1.16M-63.2% | -$709K-433% | -$133K— | —— | ||
| $531K+281% | -$293K— | —— | —— | ||
| $676K— | —— | $697K— | —— | ||
| —— | $63K-33.0% | $94K+23.7% | $76K+47.3% | ||
| $802K+68.8% | $475K+20.3% | $395K-48.5% | $767K— | ||
| —— | —— | —— | —— | ||
| $155.76M-2.3% | $159.44M-49.2% | $313.77M— | —— | ||
| —— | —— | —— | —— | ||
| -$1.16M-63.2% | -$709K-433% | -$133K— | —— | ||
| —— | —— | $1.78M-67.5% | $5.48M+14.0% | ||
| -$36.18M-23.6% | -$29.26M-15.0% | -$25.45M+23.5% | -$33.26M-129% | ||
| -$36.18M-23.6% | -$29.26M-15.0% | -$25.45M+23.5% | -$33.26M-129% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MaxCyte generate?
- MaxCyte (MXCT) generated -$28.2M in operating cash flow over the trailing twelve months.
- What is MaxCyte's free cash flow?
- After $1.2M of capital expenditures, MaxCyte's free cash flow was -$29.4M over the trailing twelve months, up 10.9% year over year.
- Where does MaxCyte's cash flow data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
